ENTRY       D11477                      Drug
NAME        Pozelimab (USAN);
            Pozelimab-bbfg;
            Veopoz (TN)
PRODUCT     VEOPOZ (Regeneron Pharmaceuticals)
FORMULA     C6418H9898N1690O2026S42
EXACT_MASS  144405.1712
MOL_WEIGHT  144494.1001
SEQUENCE    (Heqvy chain)
            QVQLQESGPG LVKPSETLSL TCTVSGDSVS SSYWTWIRQP PGKGLEWIGY IYYSGSSNYN
            PSLKSRATIS VDTSKNQFSL KLSSVTAADT AVYYCAREGN VDTTMIFDYW GQGTLVTVSS
            ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV
            FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY
            RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK
            NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG
            NVFSCSVMHE ALHNHYTQKS LSLSLG
            (Light chain)
            AIQMTQSPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKLLIYA ASSLQSGVPS
            RFAGRGSGTD FTLTISSLQP EDFATYYCLQ DFNYPWTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H95, H134-L214, H147-H203, H226-H'226, H229-H'229, H261-H321, H367-H425, H'22-H'95, H'134-L'214, H'147-H'203, H'261-H'321, H'367-H'425, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
REMARK      Product: D11477<US>
EFFICACY    Anti-inflammatory, Anti-complement C5 antibody
  DISEASE   CD55-deficient protein-losing enteropathy [DS:H00106]
  TYPE      Monoclonal antibody
COMMENT     Treatment of paroxysmal nocturnal hemoglobinuria
TARGET      C5 [HSA:727] [KO:K03994]
  PATHWAY   hsa04610(727)  Complement and coagulation cascades
BRITE       Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Complement and coagulation
                C5
                 D11477  Pozelimab (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11477
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11477
DBLINKS     CAS: 2096328-94-6
            PubChem: 384585453
///
